$MYGN
MYRIAD GENETICS INC

2015 Q4 Form 10-Q Financial Statement

#000119312516448574 Filed on February 03, 2016

View on sec.gov

Income Statement

Concept 2015 Q4 2014 Q4
Revenue $193.3M $184.4M
YoY Change 4.83% -9.63%
Cost Of Revenue $34.10M $35.10M
YoY Change -2.85% 54.25%
Gross Profit $159.2M $149.3M
YoY Change 6.63% -17.65%
Gross Profit Margin 82.36% 80.97%
Selling, General & Admin $90.80M $92.70M
YoY Change -2.05% 19.09%
% of Gross Profit 57.04% 62.09%
Research & Development $16.70M $17.50M
YoY Change -4.57% 2.4%
% of Gross Profit 10.49% 11.72%
Depreciation & Amortization $3.600M $2.900M
YoY Change 24.14% 20.83%
% of Gross Profit 2.26% 1.94%
Operating Expenses $107.5M $110.2M
YoY Change -2.45% 16.09%
Operating Profit $45.20M $36.30M
YoY Change 24.52% -56.26%
Interest Expense $100.0K $100.0K
YoY Change 0.0% -92.31%
% of Operating Profit 0.22% 0.28%
Other Income/Expense, Net -$200.0K $1.600M
YoY Change -112.5% 39.74%
Pretax Income $45.00M $37.90M
YoY Change 18.73% -54.96%
Income Tax $7.900M $13.90M
% Of Pretax Income 17.56% 36.68%
Net Earnings $37.10M $24.00M
YoY Change 54.58% -52.34%
Net Earnings / Revenue 19.19% 13.02%
Basic Earnings Per Share $0.53 $0.33
Diluted Earnings Per Share $0.50 $0.32
COMMON SHARES
Basic Shares Outstanding 70.50M shares 72.50M shares
Diluted Shares Outstanding 73.80M shares 75.40M shares

Balance Sheet

Concept 2015 Q4 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $219.3M $165.1M
YoY Change 32.83% -53.31%
Cash & Equivalents $134.7M $59.70M
Short-Term Investments $84.60M $105.4M
Other Short-Term Assets $37.70M $48.30M
YoY Change -21.95% 263.16%
Inventory $29.10M $20.17M
Prepaid Expenses $7.694M
Receivables $84.30M $81.22M
Other Receivables $5.100M $5.331M
Total Short-Term Assets $375.5M $320.1M
YoY Change 17.31% -29.57%
LONG-TERM ASSETS
Property, Plant & Equipment $61.70M $46.46M
YoY Change 32.81% 48.37%
Goodwill $177.0M $169.2M
YoY Change 4.62% 197.59%
Intangibles $186.3M $198.8M
YoY Change -6.3% 1448.26%
Long-Term Investments $66.20M $42.30M
YoY Change 56.5% -68.71%
Other Assets $5.000M $5.000M
YoY Change 0.0% -88.37%
Total Long-Term Assets $496.2M $461.8M
YoY Change 7.46% 52.81%
TOTAL ASSETS
Total Short-Term Assets $375.5M $320.1M
Total Long-Term Assets $496.2M $461.8M
Total Assets $871.7M $781.9M
YoY Change 11.49% 3.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.50M $16.83M
YoY Change -1.98% -4.34%
Accrued Expenses $47.90M $41.18M
YoY Change 16.32% -10.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $65.90M $59.84M
YoY Change 10.13% -11.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.000M $25.30M
YoY Change -92.09% 90.23%
Total Long-Term Liabilities $2.000M $25.30M
YoY Change -92.09% 90.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $65.90M $59.84M
Total Long-Term Liabilities $2.000M $25.30M
Total Liabilities $100.9M $87.61M
YoY Change 15.17% 8.55%
SHAREHOLDERS EQUITY
Retained Earnings -$68.60M -$36.98M
YoY Change 85.53% -418.67%
Common Stock $848.5M $719.0K
YoY Change 117911.13% -2.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $770.8M $694.2M
YoY Change
Total Liabilities & Shareholders Equity $871.7M $781.9M
YoY Change 11.49% 3.33%

Cashflow Statement

Concept 2015 Q4 2014 Q4
OPERATING ACTIVITIES
Net Income $37.10M $24.00M
YoY Change 54.58% -52.34%
Depreciation, Depletion And Amortization $3.600M $2.900M
YoY Change 24.14% 20.83%
Cash From Operating Activities $52.10M $52.60M
YoY Change -0.95% 10.74%
INVESTING ACTIVITIES
Capital Expenditures -$1.100M -$5.900M
YoY Change -81.36% 110.71%
Acquisitions
YoY Change
Other Investing Activities -$39.40M -$2.800M
YoY Change 1307.14% -120.59%
Cash From Investing Activities -$40.50M -$8.800M
YoY Change 360.23% -181.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 37.20M -52.20M
YoY Change -171.26% -27.2%
NET CHANGE
Cash From Operating Activities 52.10M 52.60M
Cash From Investing Activities -40.50M -8.800M
Cash From Financing Activities 37.20M -52.20M
Net Change In Cash 48.80M -8.400M
YoY Change -680.95% -37.31%
FREE CASH FLOW
Cash From Operating Activities $52.10M $52.60M
Capital Expenditures -$1.100M -$5.900M
Free Cash Flow $53.20M $58.50M
YoY Change -9.06% 16.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71500000 shares
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59700000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8500000 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.00
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71600000 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73500000 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73500000 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64800000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12500000 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68900000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.49
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68900000 shares
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
68700000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
33800000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
70900000
CY2015Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
200000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46100000
CY2015Q2 us-gaap Liabilities
Liabilities
104100000
CY2015Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
3800000
CY2015Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19000000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
700000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
745400000
CY2015Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7600000
CY2015Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
26400000
CY2015Q2 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
4900000
CY2015Q2 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
8800000
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3900000
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1500000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7000000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax
100000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8500000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77000000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
662100000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
766200000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
21100000
CY2015Q2 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
18200000
CY2015Q2 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax
100000
CY2015Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
192600000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67200000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
283600000
CY2015Q2 us-gaap Land
Land
2300000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6900000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.50
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71600000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65900000
CY2015Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
91600000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
34400000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
77500000
CY2015Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
300000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
47900000
CY2015Q2 us-gaap Goodwill
Goodwill
177200000
CY2015Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
80700000
CY2015Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
13500000
CY2015Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1900000
CY2015Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
206800000
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
187800000
CY2015Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
18500000
CY2015Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
4800000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64100000
CY2015Q2 us-gaap Assets
Assets
766200000
CY2015Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
130700000
CY2015Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
211600000
CY2015Q2 us-gaap Investments And Cash
InvestmentsAndCash
185400000
CY2015Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
85800000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
138100000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000000
CY2015Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
40600000
CY2015Q2 us-gaap Inventory Net
InventoryNet
25100000
CY2015Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
99100000
CY2015Q2 mygn Prepaid Expense Excluding Prepaid Taxes Current
PrepaidExpenseExcludingPrepaidTaxesCurrent
12500000
CY2015Q2 mygn Investments And Cash At Fair Value
InvestmentsAndCashAtFairValue
185400000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71500000 shares
CY2015Q4 us-gaap Liabilities
Liabilities
100900000
CY2015Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
4700000
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
25300000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
700000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
847800000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6200000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
27900000
CY2015Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
4800000
CY2015Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
6800000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2000000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1500000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9100000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax
100000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8800000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68600000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
770800000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
871700000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16500000
CY2015Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
17300000
CY2015Q4 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax
200000
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
186300000
CY2015Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
200000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
0
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61700000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
375500000
CY2015Q4 us-gaap Land
Land
2300000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
66300000
CY2015Q4 us-gaap Goodwill
Goodwill
177000000
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
84600000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
84600000
CY2015Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
5100000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
84600000
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
206800000
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
181500000
CY2015Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
18600000
CY2015Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
4800000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
134700000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10800000
CY2015Q4 us-gaap Assets
Assets
871700000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
171500000
CY2015Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
13500000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
0
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
66200000
CY2015Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
211600000
CY2015Q4 us-gaap Investments And Cash
InvestmentsAndCash
285600000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
84300000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
139200000
CY2015Q4 us-gaap Prepaid Taxes
PrepaidTaxes
28000000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000000
CY2015Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
66200000
CY2015Q4 us-gaap Inventory Net
InventoryNet
29100000
CY2015Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
101000000
CY2015Q4 mygn Number Of Defined Benefit Pension Plans
NumberOfDefinedBenefitPensionPlans
2 plan
CY2015Q4 mygn Prepaid Expense Excluding Prepaid Taxes Current
PrepaidExpenseExcludingPrepaidTaxesCurrent
9700000
CY2015Q4 mygn Investments And Cash At Fair Value
InvestmentsAndCashAtFairValue
285500000
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71252152 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3200000 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
1000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72600000 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.37 pure
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
3000000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
59600000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1100000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75800000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.53
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
2600000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1600000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
37300000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
343600000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1400000
us-gaap Operating Income Loss
OperatingIncomeLoss
62300000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3700000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
63800000
us-gaap Revenues
Revenues
353200000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13900000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
21600000
us-gaap Investment Income Interest
InvestmentIncomeInterest
100000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-1900000
us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
500000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1500000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
17500000
us-gaap Net Income Loss
NetIncomeLoss
40000000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
9600000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
2500000
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
-100000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-300000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
22600000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2400000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
103900000
us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
-8000000
us-gaap Income Taxes Paid
IncomeTaxesPaid
12800000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
800000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12000000
us-gaap Depreciation
Depreciation
5500000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-81100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6500000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-2400000
us-gaap Cost Of Revenue
CostOfRevenue
67800000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23800000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
20200000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
14000000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
700000
us-gaap Costs And Expenses
CostsAndExpenses
290900000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5100000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6200000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
2600000
us-gaap Share Based Compensation
ShareBasedCompensation
19000000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
178100000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15200000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
80500000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
18800000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40100000
mygn Amount Charged To Retained Earnings As Result Of Stock Repurchases
AmountChargedToRetainedEarningsAsResultOfStockRepurchases
79000000
mygn Amount Of Reduction In Common Stock As Result Of Stock Repurchases
AmountOfReductionInCommonStockAsResultOfStockRepurchases
25000000
mygn Cost Of Pharmaceutical And Clinical Services
CostOfPharmaceuticalAndClinicalServices
4900000
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
MYGN
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
4400000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Entity Central Index Key
EntityCentralIndexKey
0000899923
dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3500000 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69600000 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.36 pure
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
1700000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
65800000
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
21.38
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4000000 shares
dei Entity Registrant Name
EntityRegistrantName
MYRIAD GENETICS INC
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.82
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1500000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73100000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.78
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
us-gaap Basis Of Accounting
BasisOfAccounting
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>(1)</b></td> <td align="left" valign="top"><b>BASIS OF PRESENTATION</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the &#x201C;Company&#x201D;) in accordance with U.S. generally accepted accounting principles (&#x201C;GAAP&#x201D;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201C;SEC&#x201D;). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the fiscal year ended June&#xA0;30, 2015, included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended June&#xA0;30, 2015. Operating results for the three and six months ended December&#xA0;31, 2015 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
16100000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
5300000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
54900000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
354500000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-100000
us-gaap Operating Income Loss
OperatingIncomeLoss
88500000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4100000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
88600000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
400000
us-gaap Revenues
Revenues
376800000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11100000
us-gaap Investment Income Interest
InvestmentIncomeInterest
200000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-29800000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
100000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2100000
us-gaap Net Income Loss
NetIncomeLoss
57000000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
22300000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-100000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
100700000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
62900000
us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
28000000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
177300000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-500000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
71300000
us-gaap Share Based Compensation
ShareBasedCompensation
16300000
us-gaap Income Taxes Paid
IncomeTaxesPaid
28500000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2800000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
13500000
us-gaap Depreciation
Depreciation
7200000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
38100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6300000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1800000
us-gaap Cost Of Revenue
CostOfRevenue
65000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31600000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
84900000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
14500000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0
us-gaap Costs And Expenses
CostsAndExpenses
288300000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
70600000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
2700000
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
-200000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4100000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
16100000
us-gaap Goodwill Translation Adjustments
GoodwillTranslationAdjustments
-200000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-31500000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33900000
mygn Percent Of Employee Contribution To Deferred Savings Plan
PercentOfEmployeeContributionToDeferredSavingsPlan
0.50 pure
mygn Amount Charged To Retained Earnings As Result Of Stock Repurchases
AmountChargedToRetainedEarningsAsResultOfStockRepurchases
48500000
mygn Amount Of Reduction In Common Stock As Result Of Stock Repurchases
AmountOfReductionInCommonStockAsResultOfStockRepurchases
14900000
mygn Cost Of Pharmaceutical And Clinical Services
CostOfPharmaceuticalAndClinicalServices
12100000
mygn Employers Contribution Not To Exceed Percentage Of Employees Compensation
EmployersContributionNotToExceedPercentageOfEmployeesCompensation
0.04 pure
CY2014Q4 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2900000 shares
CY2014Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72500000 shares
CY2014Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.37 pure
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75400000 shares
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
CY2014Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
22200000
CY2014Q4 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
179200000
CY2014Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1500000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
36300000
CY2014Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
37900000
CY2014Q4 us-gaap Revenues
Revenues
184400000
CY2014Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
100000
CY2014Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1600000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
24000000
CY2014Q4 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
5200000
CY2014Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-100000
CY2014Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1700000
CY2014Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6000000
CY2014Q4 us-gaap Depreciation
Depreciation
2900000
CY2014Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3100000
CY2014Q4 us-gaap Cost Of Revenue
CostOfRevenue
35100000
CY2014Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13900000
CY2014Q4 us-gaap Costs And Expenses
CostsAndExpenses
148100000
CY2014Q4 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
1100000
CY2014Q4 us-gaap Share Based Compensation
ShareBasedCompensation
12100000
CY2014Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
92700000
CY2014Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17500000
CY2014Q4 mygn Amount Charged To Retained Earnings As Result Of Stock Repurchases
AmountChargedToRetainedEarningsAsResultOfStockRepurchases
43600000
CY2014Q4 mygn Amount Of Reduction In Common Stock As Result Of Stock Repurchases
AmountOfReductionInCommonStockAsResultOfStockRepurchases
14800000
CY2014Q4 mygn Cost Of Pharmaceutical And Clinical Services
CostOfPharmaceuticalAndClinicalServices
2800000
CY2015Q4 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3300000 shares
CY2015Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70500000 shares
CY2015Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.33 pure
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73800000 shares
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2015Q4 us-gaap Share Based Compensation
ShareBasedCompensation
7700000
CY2015Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2015Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
28300000
CY2015Q4 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
182600000
CY2015Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-300000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
45200000
CY2015Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
45000000
CY2015Q4 us-gaap Revenues
Revenues
193300000
CY2015Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
100000
CY2015Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-200000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
30300000
CY2015Q4 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
10700000
CY2015Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-200000
CY2015Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1800000
CY2015Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6800000
CY2015Q4 us-gaap Depreciation
Depreciation
3600000
CY2015Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3200000
CY2015Q4 us-gaap Cost Of Revenue
CostOfRevenue
34100000
CY2015Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14700000
CY2015Q4 us-gaap Costs And Expenses
CostsAndExpenses
148100000
CY2015Q4 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
1200000
CY2015Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90800000
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16700000
CY2015Q4 mygn Amount Charged To Retained Earnings As Result Of Stock Repurchases
AmountChargedToRetainedEarningsAsResultOfStockRepurchases
20000000
CY2015Q4 mygn Amount Of Reduction In Common Stock As Result Of Stock Repurchases
AmountOfReductionInCommonStockAsResultOfStockRepurchases
5400000
CY2015Q4 mygn Cost Of Pharmaceutical And Clinical Services
CostOfPharmaceuticalAndClinicalServices
6500000

Files In Submission

Name View Source Status
0001193125-16-448574-index-headers.html Edgar Link pending
0001193125-16-448574-index.html Edgar Link pending
0001193125-16-448574.txt Edgar Link pending
0001193125-16-448574-xbrl.zip Edgar Link pending
d105198d10q.htm Edgar Link pending
d105198dex101.htm Edgar Link pending
d105198dex311.htm Edgar Link pending
d105198dex312.htm Edgar Link pending
d105198dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mygn-20151231.xml Edgar Link completed
mygn-20151231.xsd Edgar Link pending
mygn-20151231_cal.xml Edgar Link unprocessable
mygn-20151231_def.xml Edgar Link unprocessable
mygn-20151231_lab.xml Edgar Link unprocessable
mygn-20151231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending